Amino Acid Ester Prodrugs of Floxuridine: Synthesis and Effects of Structure, Stereochemistry, and Site of Esterification on the Rate of Hydrolysis by Vig, Balvinder S. et al.
Amino Acid Ester Prodrugs of
Floxuridine: Synthesis and Effects of
Structure, Stereochemistry, and Site of
Esterification on the Rate
of Hydrolysis
Balvinder S. Vig,1 Philip J. Lorenzi,1 Sachin Mittal,1
Christopher P. Landowski,1 Ho-Chul Shin,1
Henry I. Mosberg,2 John M. Hilfinger,3 and
Gordon L. Amidon1,4
Received February 18, 2003; accepted May 23, 2003
Purpose. To synthesize amino acid ester prodrugs of floxuridine
(FUdR) and to investigate the effects of structure, stereochemistry,
and site of esterification of promoiety on the rates of hydrolysis of
these prodrugs in Caco-2 cell homogenates.
Methods. Amino acid ester prodrugs of FUdR were synthesized using
established procedures. The kinetics of hydrolysis of prodrugs was
evaluated in human adenocarcinoma cell line (Caco-2) homogenates
and pH 7.4 phosphate buffer.
Results. 3-Monoester, 5-monoester, and 3,5-diester prodrugs of
FUdR utilizing proline, L-valine, D-valine, L-phenylalanine, and D-
phenylalanine as promoieties were synthesized and characterized. In
Caco-2 cell homogenates, the L-amino acid ester prodrugs hydrolyzed
10 to 75 times faster than the corresponding D-amino acid ester pro-
drugs. Pro and Phe ester prodrugs hydrolyzed much faster (3- to
30-fold) than the corresponding Val ester prodrugs. Further, the 5-
monoester prodrugs hydrolyzed significantly faster (3-fold) than the
3,5-diester prodrugs.
Conclusions. Novel amino acid ester prodrugs of FUdR were suc-
cessfully synthesized. The results presented here clearly demonstrate
that the rate of FUdR prodrug activation in Caco-2 cell homogenates
is affected by the structure, stereochemistry, and site of esterification
of the promoiety. Finally, the 5-Val and 5-Phe monoesters exhibited
desirable characteristics such as good solution stability and relatively
fast enzymatic conversion rates.
KEY WORDS: floxuridine; prodrug; hydrolysis; stability; amino
acid; Caco-2.
INTRODUCTION
Floxuridine (FUdR, 5-fluoro-2-deoxyuridine) is a fluori-
nated pyrimidine that is primarily used for the treatment of
metastatic carcinoma of the colon or following resection of
hepatic metastases (1). FUdR and other pyrimidine analogs
have been extensively used in the treatment of a variety of
cancers for the past 40 years, and their mechanisms of action
are well understood (2). Although clinically effective, FUdR
exhibits various side effects as a result of its actions on highly
mitotic tissues such as the gastrointestinal (GI) tract and bone
marrow (2). Further, FUdR, like most other nucleoside anti-
cancer agents, also suffers from low and erratic oral absorp-
tion (3). Hence, FUdR is administered as an intravenous in-
fusion (4). Strategies that can improve the oral absorption of
FUdR and reduce its toxicity can be of great benefit. In this
regard, prodrug strategies offer maximum flexibility (5,6). In
the past, a variety of prodrugs of FUdR were synthesized to
improve its physicochemical properties and reduce toxicity.
In this regard, a variety of alkyl ester prodrugs (7–10), phos-
phoramidate prodrugs (11), and photoactivated prodrugs (12)
of FUdR have been investigated. Recently Xia et al. synthe-
sized dual prodrugs of FUdR by attaching well-known cell-
differentiating agents such as retinoic acid to FUdR (13).
The oral bioavailability of poorly absorbed drugs can
also be enhanced by targeting them to oligopeptide transport-
ers (14,15). Oligopeptide transporters are highly expressed in
the intestine and are involved in transport of di/tri-peptides,
-lactam antibiotics, ACE inhibitors, and a variety of other
clinically relevant drugs across the intestine (15,16). The en-
hanced oral bioavailability of valacyclovir and valganciclovir,
amino acid ester prodrugs of acyclovir and ganciclovir, re-
spectively, has been attributed to their enhanced intestinal
transport via oligopeptide transporters (14,17). Further, Na-
kanishi et al. (18) and Gonzalez et al. (19) recently demon-
strated that oligopeptide transporters are enriched in some
cancer epithelial cells and can be used for delivery of pep-
tidomimetic anticancer agents (20,21). We anticipate that
amino acid ester prodrugs of anticancer agents such as floxu-
ridine may also be transported by oligopeptide transporters
and could provide enhanced oral absorption or improved tar-
geting to cancer cells overexpressing these transporters. Al-
though enhanced prodrug uptake via transporters is of pri-
mary importance, activation of the prodrug following its
transport is also an essential step for drug activity; however,
this process has not been well studied. It has generally been
suggested that ubiquitous esterases and proteases are in-
volved in such activation (22–24), but the enzymes involved
have rarely been characterized. Activation of prodrugs can be
influenced by both the promoiety and the drug itself. How-
ever, there are very limited structure–activity studies evalu-
ating the influence of promoiety on the rate of hydrolysis/
activation of prodrugs. An understanding of the influence of
promoiety structural parameters on the rate of prodrug acti-
vation would therefore facilitate the design of prodrugs with
optimum stability and activation profiles.
In an effort to determine the effects of structure, stereo-
chemistry, and site of esterification of the promoiety on the
rate and extent of prodrug activation, a variety of amino acid
ester prodrugs of floxuridine (Fig. 1) were synthesized, and
their hydrolysis profiles were determined in Caco-2 cell ho-
mogenates. To evaluate the effect of structure of the promoi-
ety on the rate of hydrolysis of prodrugs, aromatic amino acid
phenylalanine (Phe), aliphatic amino acid valine (Val), and
secondary amino acid proline (Pro) were selected as promoi-
eties. To evaluate the effect of stereochemistry on the rate of
hydrolysis, L- and D-forms of Phe and Val were investigated.
Further, to evaluate the effect of site of esterification on the
rate of hydrolysis, 3-monoester, 5-monoester, and 3,5-
diester prodrugs of FUdR were investigated. The hydrolysis
of commercially available valine ester prodrugs of acyclovir
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and ganciclovir, valacyclovir and valganciclovir, respectively,
were also evaluated for comparison.
MATERIALS AND METHODS
Materials
Floxuridine was obtained from Lancaster (Windham,
NH). The tert-butyloxycarbonyl (Boc) protected amino acids,
Boc-L-Phe, Boc-D-Phe, Boc-L-Pro, Boc-L-Val, and Boc-D-Val
were obtained from Calbiochem-Novabiochem (San Diego,
CA). HPLC-grade acetonitrile was obtained from Fisher Sci-
entific Company (St. Louis, MO). N,N-Dicyclohexylcarbodi-
imide (DCC), N,N-dimethylaminopyridine (DMAP), trifluo-
roacetic acid (TFA), and all other reagents and solvents were
purchased form Aldrich Chemical Company (Milwaukee,
WI). Valacyclovir and valganciclovir were obtained as gifts
from GlaxoSmithKline, Inc. (Research Triangle Park, NC)
and Hoffmann-La-Roche, Inc. (Nutley, NJ), respectively. Cell
culture reagents were obtained from Invitrogen (Carlsbad,
CA), and cell culture supplies were obtained from Corning
(Corning, NY) and Falcon (Lincoln Park, NJ). All chemicals
were either analytic or HPLC grade.
Prodrug Synthesis
Amino acid ester prodrugs of FUdR were synthesized as
described in Fig. 2. Boc-protected amino acids (Boc-Val-OH,
Boc-D-Val-OH, Boc-Phe-OH, Boc-D-Phe-OH, or Boc-Pro-
OH) (1.5 mmole), DCC (1.5 mmole) and DMAP (0.15
mmole) were allowed to react with FUdR (1.5 mmole) in 10
ml of dry N,N-dimethylformamide (DMF). The reaction mix-
ture was stirred at room temperature for 24 h. The progress of
the reaction was monitored by TLC [dichloromethane (DC-
M):methanol, 9:1]. Each reaction yielded three products as
determined by TLC. After 24 h, the reaction mixture was
filtered, and DMF removed in vacuo at 55–60°C. The residue
was dissolved in ethyl acetate (30 ml) and washed with water
(2 × 20 ml), 0.1 N HCl (1 × 20 ml), saturated NaHCO3 (2 × 20
ml), and brine (1 × 20 ml). The organic layer was dried over
MgSO4 and concentrated in vacuo. The three intermediates
observed with TLC were separated and purified using column
chromatography (ethyl acetate:hexane, 8:5). The fractions be-
longing to each intermediate were collected and analyzed for
their purity by TLC. Pure fractions were pooled and concen-
trated in vacuo. Pure intermediates were then treated with 4
ml of TFA:DCM:water (6:3:1). After 4 h, the solvent was
removed, and the residues were reconstituted with water and
lyophilized. The TFA salts of amino acid prodrugs of FUdR
were obtained as white fluffy solids. The combined yields of
pure Val, D-Val, Phe, D-Phe, and Pro prodrugs were 32%,
33%, 37%, 34%, and 41%, respectively. The actual amounts
of each prodrug obtained and the percentage yields of the
individual prodrugs are reported below.
The purity of prodrugs was determined by HPLC. All
prodrugs were more than 93% pure. Prodrugs were easily
separated from the parent drug by HPLC. Electrospray ion-
ization mass spectra (ESI-MS) were obtained on a Thermo-
quest LCQ electrospray ionization mass spectrometer. The
observed molecular weights of all prodrugs were found to be
similar to those predicted from their expected structures. For
prodrugs such as the 3 and 5 monoesters with similar mo-
lecular weights but different HPLC retention times, structural
identity was confirmed using proton nuclear magnetic reso-
nance spectra (1H NMR), which were obtained on a 300-MHz
Bruker DPX-300 NMR spectrometer.
3-L-Valyl-FUdR: amount obtained (% yield), 17 mg (10%);
percent purity, 93%; 1H NMR (DMSO-d6) , 0.95–1.01
[6H, m, (CH3)2CH]; 2.14–2.18 (1H, m,
CH); 2.33–2.37
(2H, m, C2); 3.66–3.67 (2H, m, C5); 3.98–3.99 (1H, d,
CH); 4.08–4.09 (1H, m, C4); 5.37–5.41 (1H, m, C3);
6.17–6.24 (1H, t, C1); 8.20–8.27 (1H, d, CHCF); ESI-MS;
345.9 (M+H)+.
5-L-Valyl-FUdR: amount obtained (% yield), 67 mg (2%);
percent purity, 98%; 1H NMR (DMSO-d6) , 0.92–0.98
[6H, m, (CH3)2CH]; 2.13–2.14 (2H, m, C2); 2.25–2.34
(1H, m, CH); 3.94–3.95 (2H, m, C3 and CH); 4.23–4.24
(1H, m, C4); 4.35–4.46 (2H, m, C5); 6.14–6.19 (1H, t,
C1); 7.92–7.95 (1H, d, CHCF); ESI-MS; 346 (M+H)+.
3,5-L-Divalyl-FUdR: amount obtained (% yield), 185 mg
(19%); percent purity, 98%; 1H NMR (DMSO-d6) :
0.91–1.05 {12H, m, [(CH3)2CH]2}; 1.99–2.37 [4H, m, C2,
(CH)2], 3.96 [2H, m, (
CH)2]; 4.27 (1H, m, C4); 4.39–
4.58 (2H, m, C5); 5.35–5.36 (1H, m, C3); 6.20–6.24 (1H,
t, C1); 8.01–8.03 (1H, d, CHCF); ESI-MS; 445.1
(M+H)+.
3-D-Valyl-FUdR: amount obtained (% yield), 69 mg (10%);
percent purity, 96%; 1H NMR (DMSO-d6) : 0.96–1.01
[6H, m, (CH3)2CH]; 2.14–2.20 (1H, m,
CH); 2.33–2.34
(2H, m, C2); 3.66 (2H, m, C5); 3.98 (1H, d, CH); 4.07
(1H, m, C4); 5.36–5.37 (1H, m, C3); 6.21–6.25 (1H, t,
C1); 8.20–8.22 (1H, d, CHCF); ESI-MS; 345.9 (M+H)+.
5-D-Valyl-FUdR: amount obtained (% yield), 70 mg (10%);
percent purity, 98%, 1H NMR (DMSO-d6) : 0.93–0.98
[6H, m, (CH3)2CH]; 2.13–2.14 (2H, m, C2); 2.26–2.28
Fig. 1. Structures of amino acid ester prodrugs of floxuridine and
promoieties.
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(1H, m, CH); 3.93–4.00 (2H, m, C3 and CH), 4.23 (1H,
m, C4); 4.39 (2H, m, C5); 6.1–6.2 (1H, t, C1); 7.9–7.96
(1H, d, CHCF); ESI-MS; 346 (M+H)+.
3,5-D-Divalyl-FUdR: amount obtained (% yield), 123 mg
(13%); percent purity, 98%; 1H NMR (DMSO-d6) :
0.91–1.05 [12H, m, (CH3)2CH)2]; 1.98–2.39 [4H, m, C2,
(CH)2]; 3.96–4.03 [2H, m, (
CH)2]; 4.27 (1H, m, C4);
4.41–4.54 (2H, m, C5); 5.34 (1H, m, C3); 6.20–6.24 (1H,
t, C1); 8.01–8.03 (1H, d, CHCF); ESI-MS; 445.1
(M+H)+.
3-L-Phenylalanyl-FUdR: amount obtained (% yield), 66 mg
(9%); percent purity, 96%; 1H NMR (DMSO-d6) : 2.21–
2.26 (2H, m, C2); 3.04–3.21 (2H, m, CH2); 3.56 (2H, m,
C5); 3.71 (1H, m, CH); 4.32–4.37 (1H, m, C4); 5.19–
5.20 (1H, m, C3); 6.04–6.09 (1H, t, C1); 7.25–7.37 (5H,
m, aromatic protons); 8.15–8.18 (1H, d, CHCF); ESI-MS;
394 (M+H)+.
5-L-Phenylalanyl-FUdR: amount obtained (% yield), 131 mg
(18%); percent purity, 93%; 1H NMR (DMSO-d6) :
2.07–2.15 (2H, m, C2); 3.07–3.12 (2H, m, CH2); 3.83–
3.88 (1H, m, C3); 4.05–4.09 (1H, m, CH); 4.24–4.55 (3H,
m, C4,C5); 6.11–6.16 (1H, t, C1); 7.21–7.34 (5H, m,
aromatic protons); 7.88–7.95 (1H, d, CHCF); ESI-MS;
394 (M+H)+.
3,5-L-Diphenylalanyl-FUdR: amount obtained (% yield),
115 mg (10%); percent purity, 94%; 1H NMR (DMSO-
d6) : 2.08–2.33 (2H, m, C2); 3.05–3.19 [4H, m, (
CH2)2];
3.81–3.85 (1H, m, C4); 4.28–4.43 [4H, m, C5, (CH)2];
4.94–4.96 (1H, m, C3); 6.01–6.05 (1H, t, C1); 7.21–7.37
(10H, m, aromatic protons); 7.89–7.97 (1H, d, CHCF);
ESI-MS; 541.1 (M+H)+.
3-D-Phenylalanyl-FUdR: amount obtained (% yield), 67 mg
(9%); percent purity, 94%; 1H NMR (DMSO-d6) : 1.99–
2.24 (2H, m, C2’), 3.01–3.20 (2H, m, CH2), 3.61 (2H, m,
C5), 3.94 (1H, m, CH); 4.35 (1H, m, C4); 5.28 (1H, m,
C3); 6.07 (1H, t, C1); 7.26–7.35 (5H, m, aromatic pro-
tons); 8.15–8.24 (1H, d, CHCF); ESI-MS; 394.1 (M+H)+.
5-D-Phenylalanyl-FUdR: amount obtained (% yield), 104 mg
(14%); percent purity, 96%; 1H NMR (DMSO-d6) :
2.12–2.28 (2H, m, C2); 3.02–3.16 (2H, m, CH2); 3.79
(1H, m, C3); 4.16–4.37 (4H, m, C4, C5, CH); 6.14 (1H,
t, C1); 7.21–7.32 (5H, m, aromatic protons); 7.93–7.95
(1H, d, CHCF); ESI-MS; 394 (M+H)+.
3,5-D-Diphenylalanyl-FUdR: amount obtained (% yield);
118 mg (11%), percent purity; 95%, 1H NMR (DMSO-
d6) : 1.88–2.04 (2H, m, C2’), 3.03–3.19 (4H, m, (
CH2)2),
4.01 (1H, m, C4’), 4.23–4.44 (4H, m, C5, (CH)2), 5.14
(1H, m, C3), 6.04–6.08 (1H, t, C1’), 7.20–7.36 (10H, m,
aromatic protons), 7.91–7.98 (1H, d, CHCF), ESI-MS;
541.1 (M+H)+.
3-L-Prolyl-FUdR: amount obtained (% yield), 66 mg (10%);
percent purity, 99%; 1H NMR (DMSO-d6) : 1.86–2.43
(6H, m, C2, CH2,
CH2); 3.23–3.25 (2H, m,
CH2);
3.66–3.67 (2H, m, C5); 4.09–4.10 (1H, m, CH); 5.35–
5.39 (1H, m, C3); 6.20–6.25 (1H, t, C1); 8.22–8.24 (1H,
d, CHCF); ESI-MS; 344 (M+H)+.
5-L-Prolyl-FUdR: amount obtained (% yield), 131 mg (20%);
percent purity, 98%; 1H NMR (DMSO-d6) : 1.87–2.33
Fig. 2. Schematic of synthesis of amino acid ester prodrugs of floxuridine.
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(6H, m, C2, CH2,
CH2); 3.23–3.25 (2H, m,
CH2);
3.93–4.43 (5H, m, C3, C4,C5, CH); 6.12–6.17 (1H, t,
C1); 7.92–7.99 (1H, d, CHCF); ESI-MS; 344.1 (M+H)+.
3,5-L-Diprolyl-FUdR: amount obtained (% yield), 115 mg
(12%); percent purity, 94%; 1H NMR (DMSO-d6) :
1.53–2.33 [10H, m, C2, (CH2)2, (
CH2)2]; 3.23–3.25
[2H, m, (CH2)2]; 4.29–4.53 [5H, m, C4,C5, (
CH)2],
5.34 (1H, m, C3); 6.17–6.21 (1H, t, C1); 7.99–8.02 (1H,
d, CHCF); ESI-MS; 441.1 (M+H)+.
Cell Culture
Caco-2 cells (passage 44–52) from American Type Cul-
ture Collection (Rockville, MD) were routinely maintained in
Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal bovine serum (FBS), 1% nonessential amino acids,
1 mM sodium pyruvate, and 1% L-glutamine. Cells were
grown in an atmosphere of 5% CO2 and 90% relative humid-
ity at 37°C.
Caco-2 Cell Homogenates
Confluent Caco-2 cells were washed with phosphate-
buffered saline (PBS, pH 7.4) and then incubated with 0.05%
trypsin-EDTA at 37°C for 5–10 min. Trypsin was neutralized
by adding DMEM. The cells were washed off the plate and
spun down by centrifugation. The pelleted cells were washed
twice with pH 7.4 phosphate buffer (100 mM) and resus-
pended in pH 7.4 phosphate buffer (100 mM) to obtain a final
concentration of approximately 5 × 106 cells/ml. The hydro-
lysis reactions were carried out in 96-well plates (Corning
#3960). The Caco-2 cell suspension (600 l) was placed in a
well, and 600 l 0.5% Triton X-100 was added. The cells were
then homogenized by vigorous pipeting, and total protein was
quantified with the Bio-Rad DC Protein Assay using bovine
serum albumin as a standard.
Hydrolysis of Prodrugs in Caco-2 Cell Homogenates
Hydrolysis of prodrugs was determined in Caco-2 cell
homogenates at room temperature. The hydrolysis reaction
was initiated by adding 200 l of 1.4 mM prodrug solution
(prepared fresh in pH 7.4, 100 mM phosphate buffer) to a
reaction well containing Caco-2 cell homogenates. At various
time points (0, 5, 10, 15, 20, and 30 min), 200 l of the reaction
mixture was removed and added to a quenching plate con-
taining 200 l of ice-cold TFA in each well. Following collec-
tion of all samples, the quenching plate was centrifuged at
1800 g for 1 h at 4°C to pellet the protein precipitate. The
supernatant was removed and assayed for prodrug and the
parent drug by HPLC. Triplicate determinations of the extent
of hydrolysis of each prodrug at a given time point were con-
ducted.
Hydrolysis of Prodrugs in pH 7.4 Phosphate Buffer
The degradation profiles of the prodrugs were deter-
mined in pH 7.4 phosphate buffer (100 mM) alone in order to
obtain the contribution of nonenzymatic hydrolysis. The ex-
periments were carried out in triplicate as described above
except that each well contained pH 7.4 phosphate buffer (100
mM) without Caco-2 cell homogenates.
HPLC Analysis
The concentrations of prodrugs and their parent drugs
were determined on a Waters HPLC system (Waters Inc.,
Milford, MA). The HPLC system consisted of two Waters
pumps (Model 515), a Waters auto-sampler (WISP model
712), and a Waters UV detector (996 Photodiode Array De-
tector). The system was controlled by Waters Millennium 32
software (Version 3.0.1). Samples were injected onto a Wa-
ters Xterra C18 reversed-phase column (5 m, 4.6 × 250 mm)
equipped with a guard column. The compounds were eluted
using a gradient method. Table I lists the solvent composi-
tions, retention times, and detection wavelengths for all pro-
drugs and their parent drugs. The aqueous mobile phase (sol-
vent A) was 0.1% (v/v) TFA in distilled water, and organic
mobile phase (solvent B) was 0.1% (v/v) TFA in acetonitrile.
Standard curves generated for each prodrug, and their parent
drugs were used for quantification of integrated area under
peaks.
Data Analysis
The initial rates of hydrolysis were used to obtain the
apparent first-order rate constants and estimate the half-lives.
The apparent first-order degradation rate constants of various
Table I. HPLC Methods and Retention Times for Floxuridine Prodrugs
Prodrug
Gradient description
(% solvent B)a  (nm)
Retention time (min)
Prodrug Parent
Rt3,5 Rt3 Rt5 RtFlox
Val-FUdR 2 to 26% in 12 min 267 11.7 11.0 9.7 6.7
D-Val-FUdR 2 to 26% in 12 min 267 11.8 10.5 10.2 6.7
Phe-FUdR 2 to 34% in 16 min 267 16.3 14.7 13.1 6.7
D-Phe-FUdR 2 to 34% in 16 min 267 16.4 14.4 13.4 6.7
Pro-FUdR 0% for 6 min, followed
by 0 to 20% in 10 min
267 14.9 15.3 10.7 9.2
Valacyclovir 0% for 6 min, followed
by 0 to 14% in 7 min
254 15.2 7.1
Valganciclovir 0% for 6 min, followed
by 0 to 14% in 7 min
254 14.1 6.0
a Solvent A, 0.1% (v/v) TFA in distilled water; solvent B, 0.1% (v/v) TFA in acetonitrile; flow rate, 1 ml/min.
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prodrugs and their parent drugs at 25°C were determined by
plotting the logarithm of prodrug remaining as a function of
time. The slopes of these plots are related to the rate constant,
k, and given by
k  2.303 × slope (log C vs. time) (1)
The degradation half-lives were then estimated by the
equation,
t1/2  0.693/k (2)
Statistical significance was evaluated with GraphPad
Prism v. 3.0 by performing one-way analysis of variance with
post-hoc Tukey’s test to compare means.
RESULTS
Synthesis of FUdR Prodrugs
The aromatic amino acids L-Phe and D-Phe, the aliphatic
amino acids L-Val and D-Val, and the secondary amino acid
Pro were selected as promoieties for synthesis of FUdR pro-
drugs (Fig. 1). Amino acid ester prodrugs of FUdR were syn-
thesized as described in Fig. 2. The reaction of Boc-protected
amino acids with FUdR resulted in production of three new
intermediates as observed by TLC. The expected intermedi-
ates were Boc-protected 3-amino acid ester, 5-amino acid
ester, and 3,5-amino acid diester prodrugs of FUdR. Fol-
lowing purification by column chromatography, the Boc
group was removed by treating the pure intermediates with
TFA. After removal of excess TFA, the resulting residue was
reconstituted with water and lyophilized. The TFA salts of
3-amino acid ester, 5-amino acid ester, and 3,5-diamino
acid ester prodrugs of FUdR were obtained as white fluffy
powders. The combined yield of pure prodrugs was more than
33%. The purity of all prodrugs was 93% as determined by
HPLC. The impurities were generally the known amino acid
ester prodrugs or the parent drug. The max and molar ab-
sorptivities for parent drug, floxuridine, and its prodrugs were
found to be similar (267 nm and 0.00147 ± 0.00015 M-1,
respectively). In some cases, other unknown impurities (1–
2%) were also present. However, it was found that both the
max and the proportionality of HPLC areas and peak heights
for these unknown impurities were similar to those of pro-
drugs and floxuridine. This similarity suggests that these un-
known contaminants are probably floxuridine-related enti-
ties. The identity of the prodrugs was confirmed by electro-
spray ionization-mass spectrometry (ESI-MS) and proton
nuclear magnetic resonance (1H NMR). All prodrugs resulted
in correct molecular weight and expected 1H NMR.
Hydrolysis of FUdR Prodrugs
Nonenzymatic Hydrolysis in Phosphate Buffer
The estimated half-lives (t1/2), obtained from linear re-
gression (r2  0.95) of pseudo-first-order plots of prodrug
concentration vs. time for FUdR prodrugs in 100 mM phos-
phate buffer, pH 7.4, are listed in Table II. The results indi-
cate that the structure of the promoiety influenced the rate of
hydrolysis of amino acid ester prodrugs of FUdR. Pro ester
prodrugs (t1/2 ∼ 24 to 90 min) hydrolyzed significantly faster
than Phe (t1/2 ∼ 190 to 820 min, p < 0.001) and Val (t1/2 ∼ 1030
to 3520 min, p < 0.001) ester prodrugs. Phe ester prodrugs
hydrolyzed faster than Val ester prodrugs. The stereochem-
istry of the amino acid promoiety did not influence the rate of
hydrolysis of the ester prodrugs of FUdR in phosphate buff-
ers. Thus, hydrolysis rates (and estimated half-lives) of both
the L and D forms of Phe and of Val were similar, irrespective
of the site of esterification. With few exceptions, the site of
esterification did not influence the rate of hydrolysis of amino
acid ester prodrugs of FUdR in a significant manner. The
control prodrugs, valacyclovir and valganciclovir, exhibited
high stability (t1/2 ∼ 3790–5860 min) in pH 7.4 phosphate
buffer.
Hydrolysis of Prodrugs in Caco-2 Cell Homogenates
The estimated half-lives (t1/2) obtained from linear re-
gression (r2  0.95) of pseudo-first-order plots of prodrug
concentration vs. time for FUdR prodrugs in Caco-2 cell ho-
mogenates are also listed in Table II. The structure, stereo-
chemistry, and site of esterification of the amino acid promoi-
ety affected the hydrolysis of the amino acid ester prodrugs of
FUdR in a significant manner.
In general, Pro and Phe ester prodrugs hydrolyzed sig-
nificantly faster (p < 0.05) than their corresponding Val ester
prodrugs. L-Pro and L-Phe ester prodrugs exhibited short half-
lives of 1 to 8 min, whereas L-Val ester prodrugs exhibited
half-lives of 10 to 32 min. A similar influence of structure on
hydrolysis rates was also evident with the D-stereoisomers.
Thus, the D-Phe ester prodrugs hydrolyzed significantly faster
(p < 0.001) than their corresponding D-Val ester prodrugs.
The control prodrugs, valacyclovir and valganciclovir, exhib-
ited similar enzymatic stability (t1/2 ∼ 17–25 min) to L-Val
ester prodrugs of floxuridine (t1/2 ∼ 10–32 min).
The stereochemistry of the amino acid ester promoiety
had a profound effect on the rate of hydrolysis of prodrugs.
The L-amino acid ester prodrugs of FUdR hydrolyzed signifi-
cantly faster (p < 0.001) than the D-amino acid ester prodrugs.
Table II. Estimated Half-Lives (Expressed as Mean ± SEM) of the
Hydrolytic Degradation of Floxuridine Prodrugs in pH 7.4 Phosphate
Buffer and in Caco-2 Cell Homogenates (n  3)
Prodrug








Valacyclovir 5860 ± 1500 16.9 ± 1.0 347
Valganciclovir 3790 ± 240 25.3 ± 0.3 150
3,5-di-O-valyl 1090 ± 440 30.3 ± 0.3 36
3-O-valyl 1160 ± 230 31.8 ± 0.4 36
5-O-valyl 3520 ± 650 9.8 ± 0.5 360
3,5-di-O-D-valyl 1030 ± 54 365.0 ± 16.0 3
3-O-D-valyl 1300 ± 96 742.0 ± 7.0 2
5-O-D-valyl 1630 ± 320 392.0 ± 23.0 4
3,5-di-O-phenylalanyl 190 ± 54 7.7 ± 0.6 24
3-O-phenylalanyl 790 ± 24 2.2 ± 0.4 359
5-O-phenylalanyl 820 ± 30 2.5 ± 0.3 328
3,5-di-O-D-phenylalanyl 306 ± 30 100.0 ± 4.0 3
3-O-D-phenylalanyl 582 ± 18 196.0 ± 27.0 3
5-O-D-phenylalanyl 612 ± 18 28.6 ± 0.3 21
3,5-di-O-prolyl 24 ± 6 0.9 ± 0.0 27
3-O-prolyl 84 ± 6 4.9 ± 0.5 17
5-O-prolyl 90 ± 6 NDa NDa
a ND, Not determined.
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In case of Phe, the L-Phe ester prodrugs hydrolyzed 11- to
48-fold faster than their corresponding D-Phe ester prodrugs,
whereas for Val the L-Val ester prodrugs hydrolyzed 12- to
75-fold faster than their corresponding D-Val ester prodrugs.
Although the site of esterification greatly influenced the
hydrolysis of prodrugs by Caco-2 cell homogenates, the ef-
fects varied depending on the promoiety. Thus, in case of
L-Val ester prodrugs, enzymatic stability was in the order 5-
monoester << 3,5-diester  3-monoester prodrug. For D-
Val ester prodrugs the order of stability was 3,5-diester 
5-monoester << 3-monoester prodrug. In case of L-Phe ester
prodrugs, the 3,5-diester exhibited the highest stability, and
3-monoester and 5-monoester prodrugs exhibited similar
rates of hydrolysis. For D-Phe ester prodrugs, the 3-monoester
prodrug was most stable, followed by 3,5-diester and 5-
monoester prodrugs. In case of Pro ester prodrugs, the 3,5-
diester prodrug hydrolyzed significantly faster than the 3-
monoester prodrug.
DISCUSSION
Prodrug strategies are often used to improve the efficacy,
safety, and biopharmaceutical properties of clinically impor-
tant agents (5,6). The prodrug strategy offers a high degree of
flexibility and has several advantages over other drug delivery
strategies (5,6). Currently, a number of prodrugs are being
used for treatment of a variety of disease states. Although
alkyl groups have been extensively used as promoieties, the
use of amino acids as promoieties provides several advan-
tages: (a) a number of structurally diverse amino acids (ali-
phatic, aromatic, acidic, basic, neutral, etc.) are commercially
available, (b) there are fewer safety concerns regarding the
use of amino acids as promoieties, (c) amino acid and peptide
chemistries are well established, and (d) amino acid prodrugs
can potentially target carrier-mediated transporters for their
transport across cell membranes.
Thus, a variety of amino acid ester prodrugs of FUdR, a
well-established anticancer agent, were synthesized. FUdR
has two free hydroxyl groups that are amenable to attachment
of promoiety. Based on the site(s) of attachment of the pro-
moiety, three types of FUdR prodrugs can be obtained: the
3-monoester prodrug, the 5-monoester prodrug, and 3,5-
diester prodrug. In this study, all three types of FUdR pro-
drugs were synthesized. The promoieties selected for hydro-
lysis studies were the aromatic amino acids L-Phe and D-Phe,
the aliphatic amino acids L-Val and D-Val, and the secondary
amino acid Pro. All amino acid ester prodrugs of FUdR were
synthesized in good yield and with high purity.
An ideal prodrug should exhibit good chemical stability
but must be enzymatically converted to parent drug following
transport across the biological membrane. The desired stabil-
ity and activation characteristics of prodrug will depend on
the purpose and the route of administration of the prodrug.
However, a prodrug should exhibit as high a chemical stabil-
ity as possible as long as it is activated before or at the site of
action. Although detailed and rigorous stability studies are
important in the characterization of promising prodrug can-
didates, rapid screening of stability is helpful for identification
of such candidates. Such screening studies may reveal the
effects of structure, stereochemistry, and site of esterification
on the rate of hydrolysis of the amino acid ester prodrugs of
FUdR. In this study, chemical and enzymatic hydrolysis of the
FUdR prodrugs in pH 7.4 phosphate buffer and Caco-2 cell
homogenates, respectively, were evaluated. The hydrolysis of
commercially available valine ester prodrugs of acyclovir and
ganciclovir, valacyclovir and valganciclovir, respectively, were
also evaluated for comparison. Because both the prodrugs
and the parent drug could be simultaneously analyzed by
HPLC, the disappearance of the prodrugs and the appearance
of the parent drug were calculated. Generally, an excellent
mass balance (100 ± 2%) of loss of prodrug and generation of
parent drug was obtained. However, here only the estimated
half-lives for disappearance of the prodrugs are reported.
The results of the chemical stability studies in pH 7.4
phosphate buffer indicate that with the exception of Pro ester
prodrugs, all other FUdR prodrugs exhibited good stability.
Although detailed studies are required to evaluate the mecha-
nisms involved in the hydrolysis of FUdR prodrugs, these
prodrugs may hydrolyze by one or more mechanisms as sug-
gested by Varia and co-workers (25). The low chemical sta-
bility of Pro ester prodrugs of FUdR may result from the
higher pKa of the secondary -amino group of Pro (pKa of the
alpha amine of Pro, Val, and Phe are 10.61, 9.61, and 9.12,
respectively) (25). At pH 7.4, the -amine of Pro will be
highly ionized, and substitution of an ionized amine in the
acyl portion of the esters is known to increase the hydrolysis
of ester bond (26). The high chemical instability of Pro ester
prodrugs of FUdR renders them unsuitable for further devel-
opment. The slightly higher chemical stability of Val ester
prodrugs compared to Phe ester prodrugs may be caused by
the electron-donating isopropyl side chain of Val, which ren-
ders the ester linkage less labile, or by the excess of protons
on the  carbon of the side chain, which can hinder the nu-
cleophilic attack on carbonyl carbon as suggested by Wolfen-
den (27).
It appears that the chemical stability of the ester bond in
amino acid ester prodrugs of FUdR is influenced by the char-
acteristics of the amino acid promoieties. Further, as ex-
pected, the stereochemistry of the promoiety did not influ-
ence the chemical stability of amino acid ester prodrugs of
FUdR. In addition, as expected, the stability profiles of the
3-monoester prodrugs and the 5-monoester prodrugs in
phosphate buffer were similar. These results are consistent
with previous studies on the hydrolysis of 3- and 5-
monoalkyl esters of FUdR in 0.01 N NaOH (9), suggesting
that the site of esterification had no effect on the alkali lability
of the monoalkyl esters of FUdR (9). Although less stable
than valacyclovir and valganciclovir, the Val ester prodrugs of
FUdR exhibited the highest chemical stability of all the
FUdR prodrugs synthesized. Based on the results of the
chemical hydrolysis screening studies, Val ester prodrugs of
FUdR appear to be the most promising candidates for further
rigorous examination of stability characteristics.
Caco-2 cells are routinely used as in vitro models to
evaluate the intestinal transport and disposition of drugs and
drug candidates, and preliminary studies demonstrated sig-
nificant prodrug hydrolytic activity (28). Caco-2 cell homog-
enates were therefore used to evaluate the hydrolysis of
FUdR prodrugs. In Caco-2 cell homogenates, FUdR prodrugs
exhibited a wide range of hydrolytic profiles, with D-Val ester
prodrugs being the most stable and Pro ester prodrugs the
least. In comparison, valacyclovir and valganciclovir exhibited
intermediate stability. The rates of hydrolysis of the amino
acid ester prodrugs of FUdR were much faster in Caco-2 cell
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homogenates than in phosphate buffer, which were used as
controls for nonenzymatic hydrolysis (Table II). These results
clearly suggest that hydrolysis of prodrugs was predominantly
due to the enzymes present in Caco-2 cell homogenates. In
Caco-2 cell homogenates, the rates of hydrolysis were signifi-
cantly affected by the structure, stereochemistry, and site of
esterification of the promoiety. The Pro and Phe ester pro-
drugs hydrolyzed faster than Val ester prodrugs, suggesting
that Pro and Phe ester prodrugs exhibit higher conforma-
tional compatibility with the enzyme(s) responsible for their
hydrolysis. A similar conformational preference may also ex-
plain the influence of site of esterification on the rate of hy-
drolysis of FUdR prodrugs. The finding that L-amino acid
ester prodrugs hydrolyzed faster than the D-amino acid ester
prodrugs is consistent with previous studies with peptides and
peptidomimetic drugs that demonstrated that D-amino acid–
containing analogs were less susceptible to enzymatic hydro-
lysis (29). Finally, a comparison of the ratios of half-lives of
chemical (phosphate buffer pH 7.4) to enzymatic (Caco-2 cell
homogenates) hydrolysis indicated that the highest ratios
were obtained with the 3-Phe-, 5-Phe-, and 5-Val monoes-
ter prodrugs of FudR, which were similar to that for valacy-
clovir. Thus, the 3-Phe, 5-Phe, and 5-Val ester prodrugs of
FUdR possess desirable prodrug characteristics such as good
solution stability and relatively fast enzymatic conversion
rates. However, from a prodrug design perspective, only 5-
Phe- and 5-Val-FUdR prodrugs block the hydroxyl group
essential for the activity of FUdR. Therefore, these prodrugs
will be further evaluated in detailed stability studies.
The results of this study clearly indicate that the struc-
ture, stereochemistry, and site of esterification of the amino
acid promoiety profoundly affect the rates of activation of the
FUdR prodrugs. The significant differences in activation rates
of FUdR prodrugs in the presence of Caco-2 cell homog-
enates suggest that it may be possible to modulate the rate of
activation of the prodrug following its transport across the cell
membrane. Thus, depending on the structure of the promoi-
ety, either a rapid or slow rate of hydrolysis can be achieved
and may be beneficial in the design of a prodrug with a de-
sired half-life. A controlled rate of hydrolysis can therefore be
achieved based on the structure of promoiety.
In conclusion, the hydrolysis of amino acid ester pro-
drugs of FUdR is a function of the promoiety. A careful
selection of promoiety can lead to a controlled activation of
the prodrug. Similar studies involving structurally diverse
amino acids and nucleosidic drugs will provide further in-
sights into the role of the structure of promoiety and parent
drug in the hydrolysis of the prodrug. Such studies will even-
tually lead to a database of structure–activity correlations that
can be used to design prodrugs with optimum stability and
activation profiles.
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